GSK vs. SES
GSK (GlaxoSmithKline plc) and SES (SES AI Corp) are both stocks. GSK operates in Drug Manufacturers - General (Healthcare), while SES operates in Auto Parts (Consumer Cyclical). Over the past 5 years, GSK returned 5.34%/yr vs -36.15%/yr for SES. At a 0.05 correlation, their price movements are largely independent.
Performance
GSK vs. SES - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GSK achieves a 9.89% return, which is significantly higher than SES's -40.56% return.
GSK
- 1D
- 0.34%
- 1M
- 6.78%
- YTD
- 9.89%
- 6M
- 10.40%
- 1Y
- 34.50%
- 3Y*
- 19.84%
- 5Y*
- 5.34%
- 10Y*
- 5.35%
SES
- 1D
- 0.00%
- 1M
- -5.31%
- YTD
- -40.56%
- 6M
- -47.55%
- 1Y
- 11.83%
- 3Y*
- -20.00%
- 5Y*
- -36.15%
- 10Y*
- —
GSK vs. SES - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 9.89% | 51.23% | -5.14% | 9.71% | -33.41% | 36.34% |
SES SES AI Corp | -40.56% | -17.81% | 19.67% | -41.90% | -68.34% | -5.24% |
Correlation
The correlation between GSK and SES is -0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.04 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.01 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since Mar 1, 2021 | 0.05 |
Fundamentals
GSK:
$108.04B
SES:
$356.14M
GSK:
£2.85
SES:
-$0.22
GSK:
2.47
SES:
16.19
GSK:
3.42
SES:
1.75
GSK:
£32.78B
SES:
$21.92M
GSK:
£23.87B
SES:
$7.97M
GSK:
£11.30B
SES:
-$68.11M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK vs. SES — Risk / Return Rank
GSK
SES
GSK vs. SES - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and SES AI Corp (SES). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GSK | SES | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.02 | ||
| Sortino ratioReturn per unit of downside risk | +0.75 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.11 | +0.09 |
| Calmar ratioReturn relative to maximum drawdown | 1.58 | 0.10 | +1.48 |
| Martin ratioReturn relative to average drawdown | 3.92 | 0.17 | +3.75 |
Loading charts...
Drawdowns
GSK vs. SES - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.70%, smaller than the maximum SES drawdown of -97.58%. Use the drawdown chart below to compare losses from any high point for GSK and SES.
Loading charts...
Drawdown Indicators
| GSK | SES | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -55.70% | -97.58% | +41.88% |
Max Drawdown (1Y)Largest decline over 1 year | -18.63% | -74.08% | +55.45% |
Max Drawdown (3Y)Largest decline over 3 years | -28.46% | -91.41% | +62.95% |
Max Drawdown (5Y)Largest decline over 5 years | -50.10% | -97.58% | +47.48% |
Max Drawdown (10Y)Largest decline over 10 years | -50.10% | — | — |
Current DrawdownCurrent decline from peak | -11.92% | -90.39% | +78.47% |
Average DrawdownAverage peak-to-trough decline | -18.87% | -65.76% | +46.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.28% | 45.30% | -37.02% |
Volatility
GSK vs. SES - Volatility Comparison
The current volatility for GlaxoSmithKline plc (GSK) is 6.81%, while SES AI Corp (SES) has a volatility of 27.05%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than SES based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK | SES | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.81% | 27.05% | -20.24% |
Volatility (6M)Calculated over the trailing 6-month period | 18.49% | 76.68% | -58.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.06% | 106.91% | -79.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.08% | 114.53% | -89.45% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.89% | 111.41% | -88.52% |
Dividends
GSK vs. SES - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 3.26%, while SES has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.26% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
SES SES AI Corp | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
GSK vs. SES - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and SES AI Corp. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
GSK and SES have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SES has higher volatility (27.05%) compared to GSK (6.81%). In terms of maximum drawdown, GSK dropped -55.70% vs SES's -97.58%.
GSK currently has the higher Sharpe Ratio (1.09 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GSK and SES
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer